Rgenta Therapeutics has snagged $60 million in a Series A round participated by Highlight Capital, while IDG Capital has led Taichu Biotechnology‘s $58-million Series A funding.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
